We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genes Linked to Drug Resistance in Testicular Cancer

By LabMedica International staff writers
Posted on 03 Feb 2015
Several new genetic mutations have been revealed that could drive testicular cancer. More...
In addition, a gene has been identified, which may contribute to tumors becoming resistant to current treatments.

The main testicular germ cell tumor (TGCT) histologies are seminomas, which resemble undifferentiated primary germ cells, and non-seminomas, which show differing degrees of differentiation. Cure rates for TGCTs are generally high, due to the sensitivity of malignant testicular germ cells to platinum-based chemotherapies; however this is at the cost of an increased risk of metabolic syndrome, infertility and secondary cancer.

A team of scientists led by those at the Institute of Cancer Research (London, UK) used a genetic technique called whole-exome sequencing to examine tumor samples from 42 patients with undergoing testicular cancer treatment. Surgical specimens were snap frozen within 30 minutes of surgery and matched blood samples were collected at the time of surgery. Tumor samples were trimmed to remove surrounding normal tissue, and tumor cells were confirmed by histological assessment. Tumor and matched lymphocyte DNA were extracted by standard techniques.

Samples for whole-exome sequencing were quantified using Qubit technology (Invitrogen; Carlsbad, CA, USA) and sequencing libraries constructed from 50 ng of respective normal/tumor DNA. Library preparation was performed using 37 Mb Nextera Rapid Capture Exome kits (Illumina; San Diego, CA, USA), with enzymatic tagmentation, indexing polymerase chain reaction PCR, clean-up, pooling, target enrichment and post-capture PCR amplification/quality control performed in-house, following standardized protocols. Samples underwent paired-end sequencing using the Ilumina HiSeq2500 platform with a 100-bp read length.

The investigators uncovered a number of new chromosome duplications and other abnormalities that could contribute to the development of this cancer, as well as confirming a previous association with the V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog gene (KIT). Their study also found defective copies of a DNA repair gene called X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 2 (XRCC2) in a patient who had become resistant to platinum-based chemotherapy. They were able to verify the link between XRCC2 and platinum resistance by sequencing an additional sample from another platinum-resistant tumor.

Clare Turnbull, MD, PhD, the team leader, said, “Our study is the largest comprehensive sequencing study of testicular tumors published to date, describing their mutational profile in greater detail than has been possible using previous technologies. We have identified new potential driver mutations for this type of cancer, and provided new evidence of a link between mutations in the gene XRCC2 and platinum treatment-resistant tumors.” The study was published on January 22, 2015, in the journal Nature Communications.

Related Links:

The Institute of Cancer Research
Invitrogen 
Illumina



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.